BioLab Holdings, Inc., a Phoenix-based medical manufacturer specializing in advanced wound protection technologies, has announced a significant investment in Imbed Biosciences, Inc., an innovative company from Wisconsin. This strategic partnership focuses on the development of cutting-edge synthetic antimicrobial and tissue regeneration solutions, particularly the SAM™ Antimicrobial Technology and Microlyte®, a wound matrix derived from this technology.
This collaboration aims to enhance BioLab’s skin substitute portfolio, specifically targeting physician office settings. The goal is to address the diverse clinical needs that arise throughout the wound care continuum. Imbed’s Microlyte® is engineered using bioresorbable polymers that conform rapidly to the micro contours of wound beds, reducing microbial burden while supporting tissue regeneration. Notably, Microlyte® provides sustained silver-based antimicrobial activity for a minimum of 72 hours, creating a moist environment that facilitates healing.
Expanding Wound Care Solutions
The clinical evaluations of Microlyte® indicate promising results, showing accelerated wound area reduction and high closure rates within 12 weeks for chronic, non-healing wounds. Its fully synthetic design mitigates typical supply chain issues and variability associated with biologic matrices, offering clinicians a reliable and straightforward alternative.
Jaime Leija, President of BioLab, remarked on the partnership, stating, “Imbed Biosciences has developed one of the most forward-thinking synthetic platforms we’ve seen in wound care. This partnership allows us to expand the tools clinicians rely on, especially solutions that help streamline care for complex wounds without adding operational burden.”
Imbed’s CEO, Terry Bromley, emphasized the importance of their collaboration: “BioLab’s clinical footprint and commitment to evidence-based products make them an ideal partner as we broaden Microlyte® adoption nationwide. Together, we’re looking to set a new standard for accessibility and performance in antimicrobial wound management.”
Commercialization and Future Developments
The investment will accelerate Imbed’s commercialization strategy in the U.S., enhance distribution channels, and support the ongoing development of next-generation SAM™-based matrices. These future platforms may integrate pain-management agents and other therapeutic compounds, ensuring comprehensive care options.
Both companies will work closely with clinicians and health systems to facilitate the seamless integration of Microlyte® across various care settings, including outpatient, acute, and advanced wound care environments.
BioLab Holdings, Inc. is dedicated to optimizing the standard of care through scientifically grounded innovations. Its product line includes Membrane Wrap-Lite™ and Membrane Wrap™, which utilize human tissue allograft from amniotic membrane for wound protection.
Imbed Biosciences continues to advance the next generation of wound care, focusing on its SAM™ Antimicrobial Technology, which combines multiple therapeutic agents into ultra-thin, biocompatible matrices. This innovative approach aims to reduce infection risks, alleviate pain, and promote healing across the entire wound-care continuum.
The partnership between BioLab and Imbed marks a significant step forward in the field of wound management, promising enhanced solutions for patients and healthcare providers alike.
